Morningstar

Genmab AS GMAB

Morningstar Rating
Unlock
Stock XCSE Rating as of
DKK 1,587.50 +1.00 (0.06%)
View Full Chart
As of Delayed Price Closed

Company Report

View Archive

Strong Royalty Revenue From Darzalex Continues to Drive Growth for Narrow-Moat Genmab

Rachel Elfman

Genmab is focused on the development of monoclonal antibody and bispecific antibody therapies in oncology indications. The company's best-known drug, Darzalex (or daratumumab), was developed in partnership with Johnson & Johnson for multiple myeloma. Darzalex is now entrenched in multiple myeloma care for several lines of therapy, including the frontline setting. Additionally, Darzalex is often used in combination treatments, unlocking even greater market potential. Genmab receives royalties of up to 20% from J&J on Darzalex sales, plus milestones from the company's antibody platform partnerships.

Read Full Report

Price vs Fair Value

View History
GMAB is trading at a 674% premium.
Price
DKK 1,586.50
Fair Value
DKK 4,655.00
Uncertainty
Medium
1-Star Price
DKK 4,261.90
5-Star Price
DKK 6,828.00
Economic Moat
Smptsp
Capital Allocation
Vmrxmxln

Bulls Say, Bears Say

Bulls

Darzalex is entrenched in the standard of care for multiple myeloma, and it is unlikely any competitors will completely displace it due to its robust efficacy and well-tolerated safety profile.

Bears

The multiple myeloma market is crowded with other molecules, including immunomodulatory drugs, proteasome inhibitors, HDAC inhibitors, and other targeted therapies.

Show More

News

View All

Trading Information

Previous Close Price
DKK 1,586.50
Day Range
DKK 1,562.00–1,588.00
52-Week Range
DKK 1,562.00–2,532.00
Bid/Ask
DKK 1,584.00 / DKK 1,585.00
Market Cap
DKK 100.82 Bil
Volume/Avg
82,184 / 105,827

Key Statistics

Price/Earnings (Normalized)
17.88
Price/Sales
5.49
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Total Yield
3.56%

Company Profile

Genmab AS is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab’s proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab’s leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Large Growth
Total Number of Employees
2,526
Website
https://www.genmab.com

Competitors

Valuation

View More
Metric
GMAB
INCY
4502
Price/Earnings (Normalized)
 17.8816.3616.04
Price/Book Value
 3.254.290.85
Price/Sales
 5.493.891.52
Price/Cash Flow
 14.9195.337.61
Price/Earnings
GMAB
INCY
4502

Financial Strength

Metric
GMAB
INCY
4502
Quick Ratio
 5.021.690.66
Current Ratio
 5.031.921.26
Interest Coverage
 103.0064.571.21
Quick Ratio
GMAB
INCY
4502

Profitability

Metric
GMAB
INCY
4502
Return on Assets (Normalized)
 14.76%3.60%2.91%
Return on Equity (Normalized)
 16.93%4.83%6.11%
Return on Invested Capital (Normalized)
 13.96%1.61%4.29%
Return on Assets
GMAB
INCY
4502

Biotechnology Industry Comparables

Screen With Investor
1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Novo Nordisk AS ADR
NVO
BwngfqhdhYmns$516.0 Bil
 Vertex Pharmaceuticals Inc
VRTX
BtnwczlhzBrdmw$117.1 Bil
 Regeneron Pharmaceuticals Inc
REGN
VlpcryntJymts$111.8 Bil
 Alnylam Pharmaceuticals Inc
ALNY
LbgmdjqvHlfwxfj$34.6 Bil
 argenx SE ADR
ARGX
XdhycwdmXpm$33.0 Bil
 BioNTech SE ADR
BNTX
HvcgbkxrYly$28.5 Bil
 Moderna Inc
MRNA
HqsnxyzQfhym$23.5 Bil
 United Therapeutics Corp
UTHR
XbyxccbPmczr$15.6 Bil
 Biomarin Pharmaceutical Inc
BMRN
ZhkxydjxqQdhfjyn$13.0 Bil
 Incyte Corp
INCY
DdkyqtszTytjk$12.9 Bil

Sponsor Center